Supplementary Online Content


eFigure. HARMONY 3 trial structure and participant flow

This supplementary material has been provided by the authors to give readers additional information about their work.
**A**

1. Eligible patients

2. Treatment Period

3. Follow-up

- Albiglutide 30 mg → 50 mg QW (n=302)
- Sitagliptin 100 mg QD (n=302)
- Glimepiride 2 mg → 4 mg QD (n=307)
- Placebo injection QW (n=101)

**Study week**

-6 -4 0 104 156 164

**B**

**Run-in Failures (n=476)**
- Inclusion criteria not met (n=337)
- Exclusion criteria met (n=46)
- Withdrawal of consent (n=46)
- Noncompliance with study procedure (n=28)
- Missing (n=7)
- Other (n=12)

**Assessed for eligibility (n=1525)**

**Randomized (n=1049)**

- Placebo (n=104)
  - ≥1 dose treatment (n=101)
  - Not received allocated treatment (n=3)
  - DC active treatment (n=39)
    - Withdrew consent (n=15)
    - AE (n=5)
    - Lost to FU (n=3)
    - Noncompliance (n=6)
    - Investigator decision (n=7)
    - Terminated by sponsor (n=3)

- Sitagliptin (n=313)
  - ≥1 dose treatment (n=302)
  - Not received allocated treatment (n=11)
  - DC active treatment (n=90)
    - Withdrew consent (n=41)
    - AE (n=10)
    - Lost to FU (n=15)
    - Noncompliance (n=11)
    - Investigator decision (n=2)
    - Protocol violation (n=6)
    - Terminated by sponsor (n=5)

- Glimepiride (n=317)
  - ≥1 dose treatment (n=307)
  - Not received allocated treatment (n=10)
  - DC active treatment (n=89)
    - Withdrew consent (n=42)
    - AE (n=13)
    - Lost to FU (n=10)
    - Noncompliance (n=10)
    - Investigator decision (n=1)
    - Protocol violation (n=6)
    - Severe/repeated hypoglycaemia (n=1)
    - Terminated by sponsor (n=5)
    - Other (n=1)

- Albiglutide (n=315)
  - ≥1 dose treatment (n=302)
  - Not received allocated treatment (n=13)
  - DC active treatment (n=87)
    - Withdrew consent (n=38)
    - AE (n=20)
    - Lost to FU (n=10)
    - Noncompliance (n=6)
    - Investigator decision (n=2)
    - Protocol violation (n=5)
    - Terminated by sponsor (n=4)
    - Other (n=2)

**Completed Active Treatment to Week 104**

- (n=62)
- (n=212)
- (n=218)
- (n=215)

**ITT Population**

- (n=100)
- Safety Population (n=101)

- (n=300)
- Safety Population (n=302)

- (n=302)
- Safety Population (n=307)

- (n=297)
- Safety Population (n=302)

**QD** denotes once daily; **QW**, once weekly; **DC**, discontinue; **FU**, follow-up; **ITT**, intention to treat.